ABVC BIOPHARMA, INC. (ABVC)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 300K 600K 900K Q1 '20: 78.8K Q2 '20: 226.5K Q3 '20: 115.6K Q4 '20: 62.2K Q1 '21: 263.1K Q2 '21: 31.4K Q3 '21: 99K Q1 '22: 25.7K Q2 '22: 312.9K Q3 '22: 42.3K Q4 '22: 589K Q1 '23: 128.3K Q2 '23: 6.1K Q3 '23: 15.9K Q4 '23: 2.2K Q1 '24: 1.2K Q2 '24: 117.1K Q3 '24: 389.3K Q4 '24: 2K Q3 '25: 796K Q2 '20 Q1 '21 Q1 '22 Q4 '22 Q3 '23 Q2 '24 Q3 '25

Gross Profit Quarterly

-300K 0 300K 600K 900K Q1 '20: 74.8K Q2 '20: 222.3K Q3 '20: 106.9K Q4 '20: 60.3K Q1 '21: 261.9K Q2 '21: 30.8K Q3 '21: 98.6K Q1 '22: 23.8K Q2 '22: 304.5K Q3 '22: 31.5K Q4 '22: 323.6K Q1 '23: 68K Q2 '23: -66.9K Q3 '23: -13.7K Q4 '23: -137K Q1 '24: 928 Q2 '24: 117K Q3 '24: 389K Q4 '24: 2K Q3 '25: 796K Q2 '20 Q1 '21 Q1 '22 Q4 '22 Q3 '23 Q2 '24 Q3 '25

Operating Income Quarterly

-7.5M -5M -2.5M 0 2.5M 5M 7.5M Q3 '21: -2M Q4 '21: -6.4M Q1 '22: -6.2M Q2 '22: -2M Q3 '22: -3.7M Q4 '22: -3.1M Q1 '23: -1.9M Q2 '23: -2.2M Q3 '23: -2.2M Q4 '23: -511.8K Q1 '24: -2.8M Q2 '24: -860.1K Q3 '24: -302.3K Q4 '24: -704.6K Q1 '25: -693K Q2 '25: -2.3M Q3 '25: -2M Q4 '25: -2.2M Q1 '26: -1.6M Q2 '26: -779.5K Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income Quarterly

-9M -6M -3M 0 3M 6M 9M Q3 '21: -1.8M Q4 '21: -7.9M Q1 '22: -6M Q2 '22: -1.9M Q3 '22: -3.7M Q4 '22: -4.9M Q1 '23: -1.8M Q2 '23: -2.3M Q3 '23: -3.3M Q4 '23: -383.3K Q1 '24: -2.8M Q2 '24: -942.3K Q3 '24: -394.8K Q4 '24: -731.6K Q1 '25: -842.1K Q2 '25: -2.3M Q3 '25: -2M Q4 '25: -2.8M Q1 '26: -1.6M Q2 '26: -736.9K Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue Quarterly

0 100K 200K 300K Q1 '20: 4K Q2 '20: 4.2K Q3 '20: 8.6K Q4 '20: 1.9K Q1 '21: 1.2K Q2 '21: 646 Q3 '21: 393 Q4 '21: 2.8K Q1 '22: 1.9K Q2 '22: 8.4K Q3 '22: 10.7K Q4 '22: 265.4K Q1 '23: 60.2K Q2 '23: 73K Q3 '23: 29.6K Q4 '23: 139.2K Q1 '24: 277 Q2 '24: 190 Q3 '24: 296 Q4 '24: 0 Q2 '20 Q1 '21 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24

Operating Cash Flow Quarterly

-4.5M -3M -1.5M 0 1.5M 3M 4.5M Q3 '21: -2.2M Q4 '21: -2.5M Q1 '22: -3M Q2 '22: -3.4M Q3 '22: -513.7K Q4 '22: -461.1K Q1 '23: -1.5M Q2 '23: -899.8K Q3 '23: -1.4M Q4 '23: -430.5K Q1 '24: -955.8K Q2 '24: -211.4K Q3 '24: 60.2K Q4 '24: -702.1K Q1 '25: -539.8K Q2 '25: -894.2K Q3 '25: -964.7K Q4 '25: -587.6K Q1 '26: -894.2K Q2 '26: -244.4K Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow Quarterly

-4.5M -3M -1.5M 0 1.5M 3M 4.5M Q4 '11: -367K Q1 '12: -215.7K Q2 '12: -238.6K Q3 '12: -94.2K Q4 '12: -36.4K Q1 '13: -1.2K Q2 '13: -170 Q3 '13: 0 Q4 '21: -2.5M Q1 '22: -3.1M Q2 '22: -3.5M Q3 '22: -518.1K Q4 '22: -461.2K Q4 '23: -430.5K Q1 '12 Q3 '12 Q1 '13 Q3 '13 Q1 '22 Q3 '22 Q4 '23

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 15M 30M 45M Q1 '19: 15M Q2 '19: 17.4M Q3 '20: 19.5M Q1 '21: 24.4M Q2 '21: 24.4M Q3 '21: 26.9M Q1 '22: 29.7M Q2 '22: 3.1M Q3 '22: 3.3M Q1 '23: 3.3M Q2 '23: 3.3M Q3 '23: 4.1M Q1 '24: 9.7M Q2 '24: 11.3M Q3 '24: 12.4M Q1 '25: 15M Q2 '25: 17.4M Q3 '25: 23.3M Q1 '26: 25.4M Q2 '26: 26.1M Q2 '19 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-4.50 -3.00 -1.50 0.00 1.50 3.00 4.50 Q3 '21: -0.45 Q4 '21: -0.51 Q1 '22: -0.66 Q2 '22: -1.17 Q3 '22: -2.24 Q4 '22: -3.41 Q1 '23: -3.76 Q2 '23: -3.85 Q3 '23: -3.53 Q4 '23: -1.80 Q1 '24: -1.54 Q2 '24: -0.94 Q3 '24: -0.15 Q4 '24: -0.45 Q1 '25: -0.22 Q2 '25: -0.27 Q3 '25: -0.33 Q4 '25: -0.39 Q1 '26: -0.39 Q2 '26: -0.29 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.